ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.421,43
-1,20%
S&P 500
5.421,03
0,85%
Dow Jones
38.712,21
-0,09%
Euro vs US Dollar
1,08014
-0,11%
Bitcoin
67.840,22
-0,59%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Kanada
  5. TSXV
  6. Neovasc Inc. (NVC)

  7. Neovasc Inc. (NVC) News

NVC

Neovasc Inc. (NVC)

Neovasc Inc.
Von:
Sortieren nach:
 Showing the most relevant articles for your search:TSXV:NVC
DatumZeitQuelleÜberschriftSymbolFirma
20/06/201413h00PR Newswire (Canada)Neovasc Inc. Announces Receipt of Final Approval to Graduate to the TSXTSXV:NVCNeovasc Inc.
19/06/201413h00PR Newswire (Canada)Neovasc Inc. reports results of Annual General Meeting of ShareholdersTSXV:NVCNeovasc Inc.
12/06/201420h18PR Newswire (Canada)Neovasc earns a spot in 2014 PROFIT 500 ListTSXV:NVCNeovasc Inc.
06/06/201422h15PR Newswire (Canada)Neovasc Inc. provides initial comments on lawsuitTSXV:NVCNeovasc Inc.
22/05/201413h00PR Newswire (Canada)Neovasc Inc. reports financial results for first quarter 2014TSXV:NVCNeovasc Inc.
21/05/201416h45PR Newswire (Canada)Positive First-In-Human Experience With Neovasc's Tiara™ Transcatheter Mitral Valve Presented at EuroPCR 2014TSXV:NVCNeovasc Inc.
16/05/201413h00PR Newswire (Canada)Neovasc Inc. to begin trading on the NASDAQ Capital MarketTSXV:NVCNeovasc Inc.
13/05/201413h00PR Newswire (Canada)Neovasc Inc. Announces Upcoming Presentations at EuroPCR 2014TSXV:NVCNeovasc Inc.
08/05/201413h00PR Newswire (Canada)Neovasc Hires Industry Veteran Vicki Bebeau as Vice President, Clinical AffairsTSXV:NVCNeovasc Inc.
18/04/201400h17PR Newswire (Canada)Neovasc announces filing of shelf prospectus and application to list on NASDAQTSXV:NVCNeovasc Inc.
17/04/201413h00PR Newswire (Canada)Neovasc Inc. Reports Financial Results For 2013TSXV:NVCNeovasc Inc.
31/03/201413h00PR Newswire (Canada)COSIRA Study Data Presented at ACC.14 Confirms the Neovasc Reducer(TM) Improves Functional Capabilities in Refractory Angina ...TSXV:NVCNeovasc Inc.
26/03/201414h24Marketwired CanadaNeovasc Inc. Closes C$25 Million Bought Deal Equity FinancingTSXV:NVCNeovasc Inc.
17/03/201412h00PR Newswire (Canada)Neovasc Reducer™ for Refractory Angina Featured in Live Case Session at 10th Annual Congress of Update in Cardiology and Ca...TSXV:NVCNeovasc Inc.
04/03/201413h00PR Newswire (Canada)Neovasc Inc. Provides Update on Tiara™ Transcatheter Mitral Valve and Reducer™ ProgramsTSXV:NVCNeovasc Inc.
03/03/201421h42Marketwired CanadaNeovasc Announces C$25,152,000 Bought Deal Equity FinancingTSXV:NVCNeovasc Inc.
03/02/201413h15PR Newswire (Canada)Neovasc Inc. Announces Successful First Human Implant of Tiara™ Transcatheter Mitral ValveTSXV:NVCNeovasc Inc.
20/11/201313h28PR Newswire (Canada)Neovasc Inc. Reports Financial Results for Third Quarter of 2013TSXV:NVCNeovasc Inc.
13/11/201313h28PR Newswire (Canada)Neovasc receives first US patent for its novel Tiara(TM) transcatheter mitral valve replacement technologyTSXV:NVCNeovasc Inc.
06/11/201313h28PR Newswire (Canada)Neovasc Reducer™ Achieves Primary Endpoint in COSIRA Trial, Significantly Improving Functional Capabilities in Patients wit...TSXV:NVCNeovasc Inc.
29/10/201312h28PR Newswire (Canada)Neovasc Inc. Announces Publication of Positive Tiara™ Preclinical Data in the Journal JACC: Cardiovascular InterventionsTSXV:NVCNeovasc Inc.
24/10/201313h28PR Newswire (Canada)Neovasc Inc. announces upcoming presentations at TCT 2013 scientific symposiumTSXV:NVCNeovasc Inc.
15/08/201313h28PR Newswire (Canada)Neovasc Inc. reports financial results for second quarter of 2013TSXV:NVCNeovasc Inc.
28/05/201313h30PR Newswire (Canada)Neovasc Inc. Reports Financial Results for First Quarter of 2013TSXV:NVCNeovasc Inc.
23/05/201313h30PR Newswire (Canada)Positive Animal Data Presented at EuroPCR Sets Stage for Advancing Neovasc's Tiara(TM) Transcatheter Mitral Valve into Human ...TSXV:NVCNeovasc Inc.
21/05/201313h30PR Newswire (Canada)Registry Data Presented at EuroPCR 2013 Confirms the Neovasc Reducer™ Improves Cardiovascular Parameters in Refractory Angi...TSXV:NVCNeovasc Inc.
13/05/201313h25PR Newswire (Canada)Neovasc Inc. Completes Enrollment in COSIRA Trial Assessing Efficacy of Reducer™ Product for Treatment of Refractory AnginaTSXV:NVCNeovasc Inc.
29/04/201313h25PR Newswire (Canada)Neovasc Inc. reports financial results for 2012 year-endTSXV:NVCNeovasc Inc.
25/04/201313h30PR Newswire (Canada)Neovasc Inc. reports exercise of 1.8 million warrants for net proceeds of $2.3 millionTSXV:NVCNeovasc Inc.
28/02/201313h30PR Newswire (Canada)Neovasc's COSIRA clinical trial protocol selected for publication in peer-reviewed journalTSXV:NVCNeovasc Inc.
 Showing the most relevant articles for your search:TSXV:NVC

Kürzlich von Ihnen besucht

TG
DTE
Deutsche Telekom
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
DBI
TDXP
Tec DAX
CCOM
US500
US 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
USOTC
DTEGY
Deutsche Telekom (QX)
AMEX
SPY
SPDR S&P 500
TG
LHA
Deutsche Lufthansa
AMEX
XLV
Health Care Select Sector
DBI
DAX
DAX
TG
RHM
Rheinmetall
COIN
SOLUSD
Solana
FX
EURUSD
Euro vs US Dollar
CCOM
US100
US Tech 100
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten